Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors

A third of patients with non-small cell lung cancer (NSCLC) present with un-resectable stage III locally advanced disease and are currently treated by chemo-radiotherapy but the median survival is only about 21 months. Using an orthotopic xenograft model of lung carcinoma, we have investigated the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Hillman, Gilda G., Lonardo, Fulvio, Hoogstra, David J., Rakowski, Joseph, Yunker, Christopher K., Joiner, Michael C., Dyson, Gregory, Gadgeel, Shirish, Singh-Gupta, Vinita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145357/
https://www.ncbi.nlm.nih.gov/pubmed/24862536
http://dx.doi.org/10.1016/j.tranon.2014.04.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145357/
https://www.ncbi.nlm.nih.gov/pubmed/24862536
http://dx.doi.org/10.1016/j.tranon.2014.04.002

Ejemplares similares